Eli Lilly and Company (LLY) has just announced that its SURPASS-4 clinical trial results, published in The Lancet, have shown “superior A1C [a type of hemoglobin] and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk.”
This morning, LLY shares were trading slightly higher, at $240.40 per share.
Tirzepatide SURPASS-4 Clinical Trial
The SURPASS-4 clinical trial is a phase 3 study examining tirzepatide as a possible treatment for type 2 diabetes. According to Lilly, “the completion of the study was triggered by the accrual of major adverse cardiovascular events (MACE),” which were enough to assist with the study and assess increased cardiovascular risk. The published data — from the treatment period after 52 weeks — demonstrated that “participants taking tirzepatide maintained A1C and weight control for up to two years.”
Study Hits Primary Endpoints
The SURPASS-4 study hit all of its primary and key secondary endpoints, with all three doses of tirzepatide — 5 mg, 10 mg and 15 mg — leading to “statistically significant and superior A1C and body weight reductions” when compared to insulin glargine.
LLY has a Long-Term Technical Rank of 74. Find out what this means to you and get the rest of the rankings on LLY!
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
